18.05.2015 Geratherm Medical AG  DE0005495626

DGAP-Adhoc: Geratherm Medical AG: apoplex medical technologies and Pfizer cooperate in the field of stroke


 
Geratherm Medical AG / Key word(s): Alliance 18.05.2015 14:22 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc announcement according to § 15 of the WpHG (German Securities Trading Act) transmitted by DGAP - a company of Equity Story AG. The issuer is responsible for the contents of the announcement. apoplex medical technologies and Pfizer cooperate in the field of stroke prevention Geratherm Medical/apoplex medical, Pirmasens, 18th may 2015: Pfizer Pharma GmbH and apoplex medical technologies GmbH have signed today an agreement on a German wide cooperation in the field of stroke prevention. The aim of the cooperation is to find more patients with atrial fibrillation by the technology of apoplex medical technologies and to avoid strokes by implementing guideline conform prevention. The targeted of the cooperation is in the first step the area of general practitioners and specialized doctors. Short company profile: Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index. Geratherm Medical AG, Investor Relations Fahrenheitstraße 1, 98716 Geschwenda Tel. +49 (0)36205/98 111 E-Mail: [email protected] www.geratherm.com Emittent: Geratherm Medical AG, Fahrenheitstraße 1, 98716 Geschwenda Deutschland Tel. 036205/98 111 Fax: 036205/98 115 ISIN : DE 000 549 562 6 WKN : 549 562 Börsen : Frankfurter Wertpapierbörse /Geregelter Markt/Prime Standard Börse: Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, München, Stuttgart End of the announcement 18.05.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Geratherm Medical AG Fahrenheitstraße 1 98716 Geschwenda Germany Phone: +49 (0)36205 98-0 Fax: +49 (0)36205 98-1 15 E-mail: [email protected] Internet: www.geratherm.com ISIN: DE0005495626 WKN: 549562 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 21,03 21,52 19,85 27,47 23,94 25,85 27,10
EBITDA1,2 1,77 2,80 2,35 4,35 2,31 3,55 3,85
EBITDA-Marge3 8,42 13,01 11,84 15,84 9,65 13,73
EBIT1,4 0,63 1,99 1,05 3,04 0,59 2,07 2,40
EBIT-Marge5 3,00 9,25 5,29 11,07 2,46 8,01 8,86
Jahresüberschuss1 0,22 0,83 0,29 1,90 0,33 1,08 1,30
Netto-Marge6 1,05 3,86 1,46 6,92 1,38 4,18 4,80
Cashflow1,7 2,47 1,35 1,54 3,92 0,92 2,79 0,00
Ergebnis je Aktie8 0,14 0,23 0,11 0,41 0,02 0,19 0,24
Dividende8 0,47 0,40 0,25 0,40 0,12 0,15 0,50
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Geratherm Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549562 4,340 Halten 23,63
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
11,13 24,70 0,45 16,19
KBV KCV KUV EV/EBITDA
1,10 8,49 0,91 6,21
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,15 0,15 3,46 30.08.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 25.08.2023 - 20.06.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-18,08% -26,81% -19,63% -41,35%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Geratherm Medical AG  ISIN: DE0005495626 können Sie bei EQS abrufen


Medtech , 549562 , GME , XETR:GME